The European regulatory authority has approved the combination of I POM + LoDEX i for patients with relapsed and refractory multiple myeloma (RRMM) who have undergone at least two prior therapies including lenalidomide and bortezomib. The starting dose was 4 mg pomalidomide in 85 patients (82.5%), and 3 mg pomalidomide in 6 patients (6%) or 2 mg pomalidomide in 12 patients (11.5%) due to an absolute neutrophil count lower than 1.0 × 10 SP 3 sp /µL, or a platelets count below 20 × 10 SP 3 sp /µL or ECOG PS > 2. Dose reduction was necessary for 27% of patients due to hematological toxicity grade 3/4 (50% of patients) and non-hematological toxicity (50% of patients). Neutropenia was the most common hematologic adverse event and occurred in 32% of patients; thrombocytopenia occurred in 8.5% of patients, anemia in 9.5% of patients. [Extracted from the article]